Skip to content

NAD+evidence-first

The NAD Review
menu

evidence_review

NAD+ Patches: Do Transdermal Patches Deliver Anything?

NAD+ patches promise needle-free absorption through the skin. The honest answer: the skin barrier blocks large, charged molecules like NAD+. Here's the data.

NAD+ patches are sold as the most effortless way to "boost your NAD+" — stick a patch on your arm, wear it all day, and let the molecule seep through your skin while you skip the IV, the injection, and even the pill. The appeal is obvious. The problem is the skin itself. Your skin's outer layer exists precisely to keep large, water-loving molecules *out*, and NAD+ is about as large and water-loving as molecules get. So the central question — does a transdermal patch actually deliver NAD+ into your body? — runs straight into a wall of well-established skin-barrier science.

We'll say the conclusion plainly, because this is another NAD+ delivery format where the marketing badly outruns the data: **there is no published human study showing that an NAD+ skin patch delivers NAD+ across the skin, raises blood NAD+, or produces any measurable benefit.** And unlike the nasal route — which at least has animal data behind it — the transdermal route has the physical chemistry of the skin barrier working actively against it. This page lays out what's actually known about getting molecules through skin, why NAD+ is a near-worst-case candidate, and why patch absorption claims deserve heavy skepticism. (We sell editorial honesty here, not patches — and that scrutiny applies to every NAD+ format we cover.)

The honest headline: the skin is built to keep NAD+ out

Transdermal delivery — getting a drug through intact skin and into the bloodstream — is a real, successful technology. Nicotine, hormones, fentanyl, and scopolamine all reach the body through patches. But that success is narrow and selective, and the rules behind it are exactly what doom NAD+. Reviews of transdermal delivery are unambiguous: the outermost skin layer, the stratum corneum, is a formidable barrier, and only a small set of molecules cross it passively at meaningful rates 34.

What makes a molecule a good transdermal candidate is well characterized: it should be **small, fat-soluble (lipophilic), and effective at a low dose**. The classic distillation of this is the **"500 Dalton rule"** — the observation that molecules above roughly 500 Daltons in molecular weight essentially do not penetrate normal skin in useful amounts 2. NAD+ has a molecular weight of about 663 Daltons. It sits *above* the threshold beyond which passive skin penetration falls off a cliff — and weight is only its first strike.

Why NAD+ is a near-worst-case molecule for a patch

NAD+ (nicotinamide adenine dinucleotide) is a large, charged coenzyme central to cellular energy metabolism and DNA repair, whose tissue levels tend to fall with age — the whole rationale for trying to "restore" it 1. Every one of those structural features is a liability for crossing skin:

- **It's too big.** At ~663 Da it's over the 500-Dalton passive-penetration ceiling 2. - **It's charged and water-loving.** The stratum corneum is a lipid (fatty) barrier that favors small, *uncharged, fat-soluble* molecules. NAD+ is hydrophilic and carries charge — the opposite of what crosses skin easily 34. - **It's unstable.** NAD+ degrades readily, which complicates keeping an intact, active dose in a wear-all-day patch.

This is the same chemistry problem that haunts NAD+ at the gut wall and the nasal lining — its size and charge make every biological membrane a hard barrier. We make the identical point about the gut in our look at whether liposomal NAD+ really absorbs orally and about the nasal lining in can NAD+ nasal spray absorb through the nose?. The skin is arguably the *most* hostile of the three, because the stratum corneum evolved specifically as a barrier to keep the outside world — including molecules like NAD+ — from getting in.

A common rebuttal is "but niacinamide (a NAD+ precursor) is in tons of skincare and it works." That's true, and it's instructive: niacinamide is a *small* molecule (~122 Da), well under the 500-Dalton ceiling, which is exactly why it penetrates skin while NAD+ itself does not. Citing a small precursor's skin penetration as evidence for the giant coenzyme's penetration gets the chemistry backwards.

What it actually takes to push a big molecule through skin (and patches don't do it)

The transdermal field has spent decades trying to get large, hydrophilic molecules — peptides, proteins, vaccines — across skin, precisely *because* passive patches can't. The methods that work are active and physical: **microneedles** that pierce the stratum corneum to create micron-scale channels, plus iontophoresis, electroporation, sonophoresis, and chemical penetration enhancers 34. Microneedles in particular are the leading research strategy for delivering macromolecules through skin, and even there the reviews are candid that delivering large drugs reliably remains a challenge with significant unsolved problems around dose, stability, and reproducibility 56.

Two things follow. First, the very existence of all this machinery is an admission that a passive, drug-in-adhesive patch cannot move a molecule like NAD+ across skin — if it could, no one would be engineering microneedles. Second, the consumer "NAD+ patches" sold online are overwhelmingly *passive* patches, not microneedle arrays delivering a measured, validated dose. So even the one technology that might plausibly breach the barrier is generally not what's in the product, and none of it has been demonstrated for NAD+ in a human pharmacokinetic study.

What the real human evidence says — and it isn't a patch

Strip away the delivery format and the evidence picture is consistent across every NAD+ route we cover. The molecules with genuine human data for raising blood NAD+ are the **plain oral precursors**, not NAD+ smeared on the skin:

- **Nicotinamide riboside (NR)** is established as uniquely and orally bioavailable in mice and humans 7, and a placebo-controlled trial in healthy middle-aged and older adults showed chronic NR is well tolerated and reliably elevates blood NAD+ 9. - **NMN** raises blood NAD+ as well — largely via an indirect breakdown-and-rebuild route through the gut and liver rather than intact absorption 8 — and a randomized trial in prediabetic women found it improved muscle insulin sensitivity 10.

But here is the crucial honesty even for those well-studied precursors: reliably raising the NAD+ *biomarker* has repeatedly failed to translate into broad, proven benefits on energy, body composition, or metabolism. A pooled analysis of NAD+-precursor supplementation found the human metabolic benefits limited and inconsistent despite raised NAD+ 11. The single human study of putting NAD+ *directly* into the body — a 6-hour IV infusion — measured biochemistry, not outcomes, and remains the closest thing to direct human NAD+ data that exists 12. There is nothing remotely comparable for a transdermal patch. We walk through that whole route-by-route picture in our NAD+ therapy evidence pillar, our NAD+ injections evidence guide, and our NAD+ IV therapy evidence and cost guide.

So do NAD+ patches deliver anything? An honest verdict

Putting it together:

1. NAD+ is a large (~663 Da), charged, water-loving, unstable molecule — chemically a near-worst-case candidate for crossing skin, sitting above the 500-Dalton ceiling beyond which passive skin penetration largely fails 12. 2. The skin barrier favors small, fat-soluble molecules; getting large hydrophilic molecules through requires active methods like microneedles or iontophoresis, not a passive adhesive patch 34. 3. Even the active methods built specifically for big molecules remain a hard, partly unsolved problem — and they're generally not what's in consumer NAD+ patches 56. 4. **No human study** has shown an NAD+ patch is absorbed, raises NAD+, or does anything you'd notice. The proven ways to raise NAD+ are oral precursors 7910 — and even those raise a biomarker more reliably than they deliver felt benefits 11.

The honest verdict: *there is good chemical reason to believe a passive transdermal patch delivers little or no NAD+ across the skin, and no human evidence that it delivers any.* That doesn't make a patch dangerous — it means the core absorption claim is essentially unsupported and runs against well-established skin-barrier science. If your goal is to raise NAD+, the evidence points to inexpensive, well-characterized oral precursors, and to keeping expectations modest about what higher NAD+ actually does. To compare products, forms, and providers on dose, route, and third-party testing — and to see where the patch option honestly ranks — see our NAD+ rankings hub.

This is consumer education, not medical advice. If you have a medical condition, are pregnant, or take other medications, talk to a clinician before starting any NAD+ product.

Frequently asked questions

Do NAD+ patches actually work?

There is no published human study showing that an NAD+ skin patch delivers NAD+ across the skin, raises blood NAD+, or produces any measurable benefit. NAD+ is a large (~663 Dalton), charged, water-loving molecule, and the skin's outer barrier favors small, fat-soluble compounds — so there's strong chemical reason to doubt a passive patch delivers meaningful NAD+. The absorption claim is essentially unsupported.

Why can't NAD+ cross the skin like a nicotine patch?

Because of size and chemistry. The classic '500 Dalton rule' holds that molecules above roughly 500 Daltons don't penetrate normal skin in useful amounts. Nicotine is small (~162 Da) and fat-soluble — ideal for a patch. NAD+ is about 663 Da, charged, and water-loving — the opposite of what crosses skin passively.

Don't microneedle patches solve this?

Microneedles are the leading research approach for pushing large molecules through skin, and they can breach the barrier by piercing it. But reliably delivering macromolecules this way remains a hard, partly unsolved problem, and consumer 'NAD+ patches' are overwhelmingly passive adhesive patches, not validated microneedle arrays. No microneedle NAD+ delivery has been demonstrated in a human study.

What's the best-proven way to raise NAD+?

Oral precursors. Nicotinamide riboside (NR) is established as orally bioavailable and reliably raises blood NAD+ in placebo-controlled human trials, and NMN raises blood NAD+ as well. Even so, raising the NAD+ biomarker has not consistently produced proven benefits on energy or metabolism — so keep expectations modest. NAD+ patches have none of that human evidence behind them.

References

  1. Covarrubias AJ, Perrone R, Grozio A, Verdin E (2021). NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology. https://pubmed.ncbi.nlm.nih.gov/33353981/
  2. Bos JD, Meinardi MM (2000). The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Experimental Dermatology. https://pubmed.ncbi.nlm.nih.gov/10839713/
  3. Prausnitz MR, Langer R (2008). Transdermal drug delivery. Nature Biotechnology. https://pubmed.ncbi.nlm.nih.gov/18997767/
  4. Prausnitz MR, Mitragotri S, Langer R (2004). Current status and future potential of transdermal drug delivery. Nature Reviews Drug Discovery. https://pubmed.ncbi.nlm.nih.gov/15040576/
  5. Kenchegowda M, Angolkar M, Hani U, et al. (2025). Polymeric microneedle advancements in macromolecule drug delivery: current trends, challenges, and future perspectives. Naunyn-Schmiedeberg's Archives of Pharmacology. https://pubmed.ncbi.nlm.nih.gov/40244451/
  6. Li X, Zhang C, Zhang Y, et al. (2025). Microneedles in biomedicine: Innovations, challenges, and future prospects. Biomaterials Translational. https://pubmed.ncbi.nlm.nih.gov/41623941/
  7. Trammell SAJ, Schmidt MS, Weidemann BJ, et al. (2016). Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nature Communications. https://pubmed.ncbi.nlm.nih.gov/27721479/
  8. Yaku K, Palikhe S, Iqbal T, et al. (2025). Nicotinamide riboside and nicotinamide mononucleotide facilitate NAD+ synthesis via enterohepatic circulation. Science Advances. https://pubmed.ncbi.nlm.nih.gov/40117359/
  9. Martens CR, Denman BA, Mazzo MR, et al. (2018). Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications. https://pubmed.ncbi.nlm.nih.gov/29599478/
  10. Yoshino M, Yoshino J, Kayser BD, et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. https://pubmed.ncbi.nlm.nih.gov/33888596/
  11. Oliveira-Cruz A, Macedo-Silva A, Silva-Lima D, et al. (2024). Effects of Supplementation with NAD+ Precursors on Metabolic Syndrome Parameters: A Systematic Review and Meta-Analysis. Hormone and Metabolic Research. https://pubmed.ncbi.nlm.nih.gov/39111741/
  12. Grant R, Berg J, Mestayer R, et al. (2019). A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+. Frontiers in Aging Neuroscience. https://pubmed.ncbi.nlm.nih.gov/31572171/

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

continue_reading